Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We propose that WDFY2 acts as a tumor suppressor by serving as a gatekeeper for VAMP3 recycling.
|
31253801 |
2019 |
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
The genomic breakpoint was identified in intron 1 of CDKN2D and intron 2 of WDFY2 in patient tumor, providing direct evidence that this is a fusion gene.
|
24675677 |
2014 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of short WDFY2 protein in transfected cells appears to alter the PI3K/AKT pathway that is known to play a role in oncogenesis.
|
24675677 |
2014 |
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Overexpression of WDFY2 in prostate cancer cells DU145 and PC-3 led to the suppression of cancer cell migration and colony formation.
|
28653900 |
2017 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Overexpression of WDFY2 in prostate cancer cells DU145 and PC-3 led to the suppression of cancer cell migration and colony formation.
|
28653900 |
2017 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of WDFY2 in prostate cancer cells DU145 and PC-3 led to the suppression of cancer cell migration and colony formation.
|
28653900 |
2017 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of WDFY2 in prostate cancer cells DU145 and PC-3 led to the suppression of cancer cell migration and colony formation.
|
28653900 |
2017 |
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Our results showed that WDFY2 had lower expression level in prostate tumors than in normal tissues.
|
28653900 |
2017 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Interestingly, to confirm that WDFY2 belongs to the p63 network of cancer regulation, we analysed the impact of WDFY2 alterations, by showing its frequent deletion in different types of tumours and suggesting its expression level as a prognostic biomarker.
|
31789342 |
2019 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Interestingly, to confirm that WDFY2 belongs to the p63 network of cancer regulation, we analysed the impact of WDFY2 alterations, by showing its frequent deletion in different types of tumours and suggesting its expression level as a prognostic biomarker.
|
31789342 |
2019 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, we have uncovered WDFY2 as a tumor suppressor gene and a new potential biomarker for cancer progression.
|
28653900 |
2017 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, we have uncovered WDFY2 as a tumor suppressor gene and a new potential biomarker for cancer progression.
|
28653900 |
2017 |
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
CDKN2D-WDFY2 fusion could be an important molecular signature for understanding and classifying sub-lineages among heterogeneous high-grade serous ovarian carcinomas.
|
24675677 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
|
24675677 |
2014 |
Ovarian Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
|
24675677 |
2014 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
|
24675677 |
2014 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
|
24675677 |
2014 |
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
WDFY2 is frequently lost in metastatic cancers, most predominantly in ovarian and prostate cancer.
|
31253801 |
2019 |
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
WDFY2 is frequently lost in metastatic cancers, most predominantly in ovarian and prostate cancer.
|
31253801 |
2019 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
WDFY2 restrains matrix metalloproteinase secretion and cell invasion by controlling VAMP3-dependent recycling.
|
31253801 |
2019 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
WDFY2, which is found to be a cancer-specific fusion gene with CDKN2D in ovarian cancer, is a new gene with unknown function in carcinogenesis.
|
28653900 |
2017 |
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
WDFY2, which is found to be a cancer-specific fusion gene with CDKN2D in ovarian cancer, is a new gene with unknown function in carcinogenesis.
|
28653900 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
WDFY2, which is found to be a cancer-specific fusion gene with CDKN2D in ovarian cancer, is a new gene with unknown function in carcinogenesis.
|
28653900 |
2017 |
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
WDFY2, which is found to be a cancer-specific fusion gene with CDKN2D in ovarian cancer, is a new gene with unknown function in carcinogenesis.
|
28653900 |
2017 |